Loxapine for the treatment of psychosis in Lewy body dementia: A case report
Abstract
Lewy body dementia (LBD) is a progressive neurological disorder characterized by dementia, parkinsonism, and psychotic symptoms. Treating psychosis in LBD is particularly challenging, especially given the high risk of extrapyramidal effects of antipsychotics commonly associated with this population. If treatment with an antipsychotic is warranted, low-potency antipsychotics are preferred; however, they may not be suitable for all patients because of adverse effect profiles, safety concerns, or logistical barriers. This case study illustrates how a patient diagnosed with LBD and unable to tolerate or access commonly used antipsychotics was effectively treated with low-dose loxapine.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.